Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Dr. Jonathan Kulbersh Discusses the Recent U.S. FDA Approval of Allergen’s Juvéderm Volbella for the Lips and Perioral Rhytids
  • USA - English


News provided by

Goldman Marketing Group

Jun 27, 2016, 06:00 ET

Share this article

Share toX

Share this article

Share toX

Dr. Jonathan Kulbersh - Carolina Facial Plastics
Dr. Jonathan Kulbersh - Carolina Facial Plastics
Youtube
Youtube

"The minimal swelling attribute alone will likely make Volbella the most popular lip filler once it is released,” said Dr. Kulbersh

Post this

Charlotte, NC (PRWEB) June 27, 2016 -- The United States FDA recently approved the use of the dermal filler, Volbella, starting in October of 2016, according to Yahoo Finance. Volbella is part of the Juvéderm family, created by the pharmaceutical powerhouse Allergen. Juvéderm is primarily used as a dermal filler for the lips, cheeks, and temples, tear troughs, and smile lines. It is composed of hyaluronic acid, a natural substance found within the human body, commonly in the eyes. Allergen took the best things about Juvéderm and enhanced it, making a filler specifically for the lips and mouth, in the form of Volbella.

Read about Juvéderm here: https://CarolinaFacialPlasticSurgery.com/What-You-Need-to-Know-When-You-Get-Juvederm-in-Charlotte/

“Volbella is a great addition to the dermal filler family,” said Dr. Kulbersh. “Lip plumping is probably one of the most common procedures I perform at my office. With the media exposure of reality stars like Kylie Jenner to musician Iggy Azalea undergoing lip injection procedures, the popularity of lip injections has skyrocketed. This trend obviously didn’t go unnoticed by Allergen and they decided to create a filler specifically for the lips, to improve the quality and longevity of the injections for their consumers.”

Learn about Lip Augmentation: https://CarolinaFacialPlasticSurgery.com/Non-Surgical-Procedures/Lip-Augmentation/

During clinical trials, it was noted that Volbella was less painful when injected, caused less swelling than its predecessor, and provided a more natural-looking result. This can be primarily attributed to the use of Vycross, which blends different molecular weights of hyaluronic acid allowing for a lower concentration and higher gel duration.

“From what I understand, Volbella was developed to become the first-choice filler to be used for the lips. I’ve heard nothing but good things about the product. The majority of patients, even when you warn them that there will most likely be swelling after having lip injections, are surprised by how inflated their lips become, so the minimal swelling attribute alone will likely make Volbella the most popular lip filler once it is released,” said Dr. Kulbersh. “Futhermore, the fact that it lasts for up to year, when Juvéderm only lasts a maximum of six months, will make Volbella even more in demand.”

Volbella has been available in Europe since 2011, and it has since expanded to Asia and Canada after positive reviews and popular demand. It is now distributed in more than 70 countries, with the United States being next. Juvéderm Volbella will be available for use in October of 2016.

“It was only a matter of time until Volbella made its way to the United States. Allergen Juvéderm always deliver quality products, and after all the positive feedback the medical world has been hearing, we were very excited to learn that the FDA approved Volbella usage domestically. What’s not to like about less pain, a more natural look, less swelling, and a longer lasting result? We are very eager to see how popular Volbella becomes and to hopefully test it in our own offices very soon,” concluded Dr. Kulbersh.

Double board-certified facial plastic surgeon and fellowship-trained in facial plastic and reconstructive surgery, Dr. Jonathan Kulbersh is the founder and director of Carolina Facial Plastics in Charlotte, North Carolina. Dr. Kulbersh received training in facial plastic surgery in Beverly Hills with renowned surgeons, Babak Azizzadeh MD FACS, Paul Nassif MD FACS (well known for his show Botched), and Guy Massry MD, and has expertise in facial rejuvenation procedures, including facelift, rhinoplasty, eyelift and injectables (Botox and fillers). Additionally, as an expert in the function of facial nerves, Dr. Kulbersh has a special interest in patients with facial paralysis and Bell’s palsy. Dr. Kulbersh has published numerous articles, as well as chapters of medical textbooks, including Master Techniques in Blepharoplasty and Periorbital Rejuvenation.

For more information please visit http://www.CarolinaFacialPlasticSurgery.com.

Carolina Facial Plastics
6849 Fairview Road #200
Charlotte, North Carolina 28210
(704) 842-3644
info(at)CarolinaFacialPlastics(dot)com

Risa Goldman, Goldman Marketing Group, +1 818-861-7092, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.